Navigation Links
Lupin Gets DCGI Nod For Phase II Clinical Trials On Desoside-P

Pharma company Lupin Ltd today said it has received approval from the Drugs Controller General (India) (DCGI) to conduct Phase II clinical trials for the molecule LL-42 18 (Desoside-P).//

The company received permission to continue Phase II clinical trials on the Psoriasis pure compound, LL-42 18, after DCGI found the clinical Phase I data of the molecule to be satisfactory.

Lupin informed the Bombay Stock Exchange that it intends to begin clinical trials at 5-6 centres immediately.

'We are delighted that our Phase I data has been found to be satisfactory for us to proceed with further clinical trials. We are very excited with taking the molecule forward and look forward to meeting this otherwise unmet market need,' Company Chairman Desh Bandhu Gupta said.

LL-4218, a pure molecule, is obtained from a plant source and is intended for the treatment of chronic stable plaque type psoriasis. This molecule's novel mechanism of action leads to marked psoriatic lesion improvement without any toxic effects.

The company said it also has three other new chemical entities in various stages of clinical trials.

Source:PTI News
'"/>




Page: 1

Related medicine news :

1. Lupin flour may cause peanut allergy like reactions
2. Lupin Gets USFDA Approval For Quinapril Tablets
3. US Court Rules Against Lupin in Ramipril Patent Case
4. Lupin Gets USFDA Approval for Meloxicam
5. Lupin Gets Tentative Nod from FDA for Antidepressant Drug
6. SARS-Free Taiwan to Mark End Phase of Global Fight
7. Spray on contraceptive clears Phase I trial
8. Phase 3 trials of two multi-kinase inhibitors against cancer
9. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
10. Phase II trails of new HIV vaccine to be held in South Africa
11. FDA approves Phase 0 trial which tests experimental drugs on humans
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/18/2017)... , ... January 18, 2017 , ... ... asset protection and financial planning services to families and business owners in the ... aimed at supporting children with developmental disabilities. , The Lakemary Center is a ...
(Date:1/18/2017)... ... January 18, 2017 , ... Catalent ... for drugs, biologics and consumer health products, today announced that Mr. Michael Merges, ... upcoming WCBP Conference, to be held at the Mayflower Hotel, Washington DC, on ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... the revolutionary Active Brake Technology (ABT), an innovative braking system that allows skaters ... Brake Technology addresses one of the biggest concerns of beginner and intermediate skaters ...
(Date:1/17/2017)... Michigan (PRWEB) , ... January 17, 2017 , ... January is National Stalking Awareness ... who choose to lurk in the corners and commit the crime of stalking, a very ... use and addiction, an often overlooked factor in stalking and other crimes. , “Stalking: know ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... point of difference. Eden Activewear is a stand-out company for several differences from ... online and only manufacture on demand, this is called 'Agile' manufacturing - ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan. 18, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, announces ... DMT210, in a Phase 2 acne rosacea study. ... downregulate the proinflammatory cytokines in the skin responsible ... rosacea. This clinical trial, DMT210-003, ...
(Date:1/18/2017)... Safe Rx LLC and Good Day Pharmacy, ... Loveland, Colorado , today announced the availability ... Day locations.     "Patients with prescriptions prone ... storage," said Milton Cohen , President & CEO ... a cup of coffee, you can protect your children ...
(Date:1/18/2017)... In China , we say Health is ... China,s Healthy Strategy originates. 2016 is ... and Social Development of the People,s Republic of ... council of the People,s Republic of China ... plan, identifying medical devices as one of the main breakthrough ...
Breaking Medicine Technology: